Start the conversation
Imagine if treating a case of cancer was as simple as your body taking out the "trash," or in other words, ridding itself of cancer-causing cells.
Hold that thought. Because a tech platform with that very task in mind is set to hit the market sooner than you think and will target a field set to be worth more than $160 billion.
See, right now, several life sciences firms are hard at work perfecting a new class of drugs known as "degraders."
As it happens, the root of many diseases lies in misguided proteins that bind together. So, the ultimate goal of "degrader" research is to come up with a new class of drugs that activate the body's own molecular trash disposal systems.
This is one of the most exciting breakthroughs I've come across in many years. I believe it brings us closer to the day when one pill can cure dozens of (if not all) diseases.
And in a moment, I'm going to reveal a way investors can target the entire class of protein degraders with one savvy move…
About the Author
Michael A. Robinson is one of the top financial analysts working today. His book "Overdrawn: The Bailout of American Savings" was a prescient look at the anatomy of the nation's S&L crisis, long before the word "bailout" became part of our daily lexicon. He's a Pulitzer Prize-nominated writer and reporter, lauded by the Columbia Journalism Review for his aggressive style. His 30-year track record as a leading tech analyst has garnered him rave reviews, too. Today he is the editor of the monthly tech investing newsletter Nova-X Report as well as Radical Technology Profits, where he covers truly radical technologies – ones that have the power to sweep across the globe and change the very fabric of our lives – and profit opportunities they give rise to. He also explores "what's next" in the tech investing world at Strategic Tech Investor.